{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:07:14Z","timestamp":1789236434293,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceuticals USA, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with ulcerative colitis (UC) typically receive a targeted inflammatory bowel disease therapy after treatment with conventional therapies and after the development of significant morbidity. Evidence suggests that early biologic treatment after diagnosis could improve treatment response and prevent disease complications compared with delayed biologic treatment after conventional therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RALEE was a retrospective study using claims data from IBM\u00ae MarketScan\u00ae Research Databases between January 1, 2016 and December 31, 2019. Adults with UC and at least one claim for vedolizumab were categorized into Early or Delayed Vedolizumab groups according to whether they had received vedolizumab within 30 days of diagnosis or after conventional therapy (5-aminosalicylates, corticosteroids, and immunomodulators), respectively. Treatment response was assessed at 2, 6, and 12 months after vedolizumab treatment initiation and was analyzed with logistic regression (bivariate).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At 2 months, Delayed Vedolizumab was associated with significantly higher odds of nonresponse than Early Vedolizumab (odds ratio [OR], 2.509; 95% confidence interval [CI], 1.28-4.90). Delayed Vedolizumab was not significantly associated with odds of nonresponse at 6 months (OR, 1.173; 95% CI, 0.72-1.90) or at 12 months (OR, 0.872; 95% CI, 0.55-1.37). Mean total healthcare costs were similar in the Early Vedolizumab ($6492) and Delayed Vedolizumab ($5897) groups, although there were small differences in costs from different types of claims.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients who received vedolizumab early after UC diagnosis were less likely to experience nonresponse at 2 months and incurred similar healthcare costs at 12 months compared with patients who received delayed vedolizumab.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otae061","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T18:03:00Z","timestamp":1729620180000},"source":"Crossref","is-referenced-by-count":5,"title":["Real-World Treatment Outcomes Associated With Early Versus Delayed Vedolizumab Initiation in Patients With Ulcerative Colitis"],"prefix":"10.1093","volume":"6","author":[{"given":"Noa","family":"Krugliak Cleveland","sequence":"first","affiliation":[{"name":"University of Chicago Medicine, Inflammatory Bowel Disease Center , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3469-6088","authenticated-orcid":false,"given":"Ninfa","family":"Candela","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc. , Lexington, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Carter","sequence":"additional","affiliation":[{"name":"OPEN Health , Bethesda, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Kuharic","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Qian","sequence":"additional","affiliation":[{"name":"OPEN Health , Bethesda, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-3156","authenticated-orcid":false,"given":"Zhaoli","family":"Tang","sequence":"additional","affiliation":[{"name":"OPEN Health , Bethesda, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Turpin","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc. , Lexington, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine, Inflammatory Bowel Disease Center , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"issue":"1","key":"2024110507510913000_CIT0001","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cgh.2019.07.005","article-title":"Ulcerative colitis and Crohn\u2019s disease have similar burden and goals for treatment","volume":"18","author":"Le Berre","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"8","key":"2024110507510913000_CIT0002","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.3390\/jcm9082646","article-title":"Early intervention in ulcerative colitis: ready for prime time","volume":"9","author":"Solitano","year":"2020","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"2024110507510913000_CIT0003","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000504092","article-title":"Treatment algorithm for mild and moderate-to-severe ulcerative colitis: an update","volume":"101","author":"Burri","year":"2020","journal-title":"Digestion."},{"issue":"10","key":"2024110507510913000_CIT0004","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cgh.2015.04.185","article-title":"Detection of dysplasia or cancer in 3.5% of patients with inflammatory bowel disease and colonic strictures","volume":"13","author":"Fumery","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"2024110507510913000_CIT0005","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2012.01.010","article-title":"Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies","volume":"10","author":"Jess","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"10","key":"2024110507510913000_CIT0006","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.cgh.2020.10.039","article-title":"Contemporary risk of surgery in patients with ulcerative colitis and Crohn\u2019s disease: a meta-analysis of population-based cohorts","volume":"19","author":"Tsai","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2024110507510913000_CIT0007","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1053\/j.gastro.2022.01.023","article-title":"What does disease progression look like in ulcerative colitis, and how might it be prevented","volume":"162","author":"Krugliak Cleveland","year":"2022","journal-title":"Gastroenterology."},{"issue":"7","key":"2024110507510913000_CIT0008","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/apt.14526","article-title":"Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation","volume":"47","author":"Gordon","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"2024110507510913000_CIT0009","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3748\/wjg.v25.i9.1142","article-title":"Conventional therapy for moderate to severe inflammatory bowel disease: a systematic literature review","volume":"25","author":"Dami\u00e3o","year":"2019","journal-title":"World J Gastroenterol."},{"issue":"12 Suppl","key":"2024110507510913000_CIT0010","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.amjgastroenterol.2003.11.002","article-title":"Maintenance therapy for inflammatory bowel disease","volume":"98","author":"Feagan","year":"2003","journal-title":"Am J Gastroenterol."},{"key":"2024110507510913000_CIT0011","doi-asserted-by":"crossref","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"2024110507510913000_CIT0012","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis."},{"issue":"4","key":"2024110507510913000_CIT0013","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/14712598.2019.1666101","article-title":"Modern use of 5-aminosalicylic acid compounds for ulcerative colitis","volume":"20","author":"Le Berre","year":"2020","journal-title":"Expert Opin Biol Ther."},{"issue":"6","key":"2024110507510913000_CIT0014","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2020.02.009","article-title":"Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases","volume":"18","author":"Beaugerie","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"23","key":"2024110507510913000_CIT0015","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.3390\/jcm10235551","article-title":"Treatment targets in ulcerative colitis: is it time for all in, including histology","volume":"10","author":"Wetwittayakhlang","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"2024110507510913000_CIT0016","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"12","key":"2024110507510913000_CIT0017","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2024110507510913000_CIT0018","doi-asserted-by":"crossref","first-page":"e00128","DOI":"10.14309\/ctg.0000000000000128","article-title":"Treatment pathways leading to biologic therapies for ulcerative colitis and Crohn\u2019s disease in the United States","volume":"11","author":"Siegel","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"4","key":"2024110507510913000_CIT0019","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/MIB.0000000000001048","article-title":"Communication between physicians and patients with ulcerative colitis: reflections and insights from a qualitative study of in-office patient-physician visits","volume":"23","author":"Rubin","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2024110507510913000_CIT0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.gastro.2016.09.046","article-title":"Management strategies to improve outcomes of patients with inflammatory bowel diseases","volume":"152","author":"Colombel","year":"2017","journal-title":"Gastroenterology."},{"issue":"8","key":"2024110507510913000_CIT0021","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"issue":"4","key":"2024110507510913000_CIT0022","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/apt.15113","article-title":"Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation","volume":"49","author":"Osterman","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"2024110507510913000_CIT0023","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s10620-019-05570-1","article-title":"Vedolizumab concentrations are associated with long-term endoscopic remission in patients with inflammatory bowel diseases","volume":"64","author":"Yarur","year":"2019","journal-title":"Dig Dis Sci."},{"issue":"5","key":"2024110507510913000_CIT0024","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cgh.2023.10.029","article-title":"ENTERPRET: a randomized controlled trial of vedolizumab dose optimization in patients with ulcerative colitis who have early nonresponse","volume":"22","author":"Jairath","year":"2024","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2024110507510913000_CIT0025","doi-asserted-by":"crossref","first-page":"2079582","DOI":"10.1155\/2016\/2079582","article-title":"Similar clinical and surgical outcomes achieved with early compared to late anti-TNF induction in mild-to-moderate ulcerative colitis: a retrospective cohort study","volume":"2016","author":"Ma","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"12","key":"2024110507510913000_CIT0026","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.cgh.2018.12.040","article-title":"Shorter disease duration is associated with higher rates of response to vedolizumab in patients with Crohn\u2019s disease but not ulcerative colitis","volume":"17","author":"Faleck","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2024110507510913000_CIT0027","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology."},{"issue":"3","key":"2024110507510913000_CIT0028","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/apt.14430","article-title":"Market share and costs of biologic therapies for inflammatory bowel disease in the USA","volume":"47","author":"Yu","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"issue":"12","key":"2024110507510913000_CIT0029","doi-asserted-by":"crossref","first-page":"e0145087","DOI":"10.1371\/journal.pone.0145087","article-title":"A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases","volume":"10","author":"Huoponen","year":"2015","journal-title":"PLoS One."},{"issue":"4","key":"2024110507510913000_CIT0030","doi-asserted-by":"crossref","first-page":"e0142481","DOI":"10.1371\/journal.pone.0142481","article-title":"Evolution of costs of inflammatory bowel disease over two years of follow-up","volume":"11","author":"van der Valk","year":"2016","journal-title":"PLoS One."},{"issue":"5","key":"2024110507510913000_CIT0031","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a lancet gastroenterology & hepatology commission","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2024110507510913000_CIT0032","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/apt.13948","article-title":"Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus","volume":"45","author":"Vuitton","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2024110507510913000_CIT0033","doi-asserted-by":"crossref","first-page":"otad061","DOI":"10.1093\/crocol\/otad061","article-title":"Dose escalation of biologics in biologic-naive patients with ulcerative colitis: outcomes from the ODESSA-UC study","volume":"5","author":"Ghosh","year":"2023","journal-title":"Crohns Colitis 360."},{"issue":"10","key":"2024110507510913000_CIT0034","first-page":"657","article-title":"What to do when biologic agents are not working in inflammatory bowel disease patients","volume":"11","author":"Dalal","year":"2015","journal-title":"Gastroenterol Hepatol (N Y)"}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae061\/59969936\/otae061.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/6\/4\/otae061\/60420301\/otae061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/6\/4\/otae061\/60420301\/otae061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T07:51:56Z","timestamp":1730793116000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otae061\/7831421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otae061","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,10,1]]},"article-number":"otae061"}}